The warning, dated June 13 and acknowledged on June 17, 2025, was issued by SEBI’s Deputy General Manager. This violation relates to failure to comply with pre-clearance requirements as stipulated in the SEBI (Prohibition of Insider Trading) Regulations, 2015.
Also Read: Neuland Labs announces ₹342-crore investment to enhance capacity in Telangana facilities
The company noted that this issue involves a specific individual and emphasized that the warning is of an administrative nature. It also stated that there will be no significant effect on its financials, operations, or other business functions due to this situation.Fourth Quarter
The net profit for the period dropped by 59% year-on-year to ₹27.8 crore. The quarterly revenue was recorded at ₹328 crore, reflecting a 15% decrease from ₹385 crore reported in the same quarter last year. Neuland’s EBITDA for this quarter declined 52% compared to the previous year, amounting to ₹51.1 crore, with margins contracting to 16% from 27.8% in the previous fiscal year.
The company experienced a reduction in total revenue in FY25 compared to FY24. Additionally, operating margins declined in accordance with initial expectations for the fiscal year. CMS revenues reached ₹637 crore, primarily driven by commercial-stage molecules. Despite the revenue downturn, the customer base has expanded.
Also Read: Neuland Laboratories shares fall 4% after equity worth ₹780 crore exchanges hands
Neuland Laboratories anticipates a revival in its growth trajectory in FY26 and maintains a positive outlook for both its short- and long-term growth prospects.
Shares of Neuland Laboratories Ltd closed at ₹12,600.00, down by ₹236.85, or 1.85%, on the BSE.
